• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Cornelia Zou

Articles by Cornelia Zou

Diving further into immuno-oncology, Ono, BMS ink deal for EP4 antagonist

Dec. 19, 2017
By Cornelia Zou

HONG KONG – Osaka, Japan-based Ono Pharmaceutical Co. Ltd. entered a license agreement with Bristol-Myers Squibb Co. for the development and commercialization of its compound, ONO-4578, a selective antagonist of EP4, a prostaglandin E2 (PGE2) receptor. An oral antagonist of EP4 developed using mouse models, ONO-4578 has showed an antitumor effect by improving immunosuppressive tumor microenvironment, and Ono already started a phase I study of the compound in Japan.


Read More

Enleofen discovers new target for fibrosis therapy

Nov. 21, 2017
By Cornelia Zou
HONG KONG – Enleofen Bio Pte Ltd., of Singapore, said it has discovered a key target for the treatment of fibrosis, which could significantly improve the therapies by offering more effective options with fewer side effects to the patients.
Read More

Enleofen discovers new target for fibrosis therapy

Nov. 15, 2017
By Cornelia Zou
HONG KONG – Enleofen Bio Pte Ltd., of Singapore, said it has discovered a key target for the treatment of fibrosis, which could significantly improve the therapies by offering more effective options with fewer side effects to the patients.
Read More

Pexidartinib hits phase III endpoint, shrinks tumors

Nov. 8, 2017
By Cornelia Zou
HONG KONG – In a pivotal phase III study, Tokyo-based Daiichi Sankyo Co. Ltd.'s pexidartinib met its primary endpoint of tumor response, measured by size reduction, in patients with symptomatic tenosynovial giant cell tumor (TGCT).
Read More

Fosun’s Henlius closing in on China’s first biosimilar nod; HLX-01 under review

Nov. 8, 2017
By Alex Ho and Cornelia Zou
HONG KONG – With a series of advancements in the area of biosimilar development, China’s Shanghai Fosun Pharmaceutical Group Co. Ltd. is getting closer to becoming the first domestic company to market a biosimilar product in China.
Read More

Pexidartinib hits phase III endpoint, shrinks tumors

Nov. 2, 2017
By Cornelia Zou
HONG KONG – In a pivotal phase III study, Tokyo-based Daiichi Sankyo Co. Ltd.'s pexidartinib met its primary endpoint of tumor response, measured by size reduction, in patients with symptomatic tenosynovial giant cell tumor (TGCT).
Read More

Basic science to POC: startup Bionetix takes translational approach

Oct. 25, 2017
By Cornelia Zou
HONG KONG – Established in February, South Korean biotech startup Bionetix Inc. has already secured a partnership with Southern Research to develop cancer drugs, and plans to move into the clinic with a lead program targeting glaucoma in 2019.
Read More

Chi-Med, Astrazeneca report early, positive results for lung cancer candidate

Oct. 25, 2017
By Cornelia Zou
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) and Astrazeneca plc released positive preliminary safety and anti-tumor activity data of co-developed potential first-in-class inhibitor savolitinib in combination with other immunotherapy agents from two phase Ib/II experiments.
Read More

Basic science to POC: startup Bionetix takes translational approach

Oct. 20, 2017
By Cornelia Zou
HONG KONG – Established in February, South Korean biotech startup Bionetix Inc. has already secured a partnership with Southern Research to develop cancer drugs, and plans to move into the clinic with a lead program targeting glaucoma in 2019.
Read More

Chi-Med, Astrazeneca report early, positive results for lung cancer candidate

Oct. 19, 2017
By Cornelia Zou
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) and Astrazeneca plc released positive preliminary safety and anti-tumor activity data of co-developed potential first-in-class inhibitor savolitinib in combination with other immunotherapy agents from two phase Ib/II experiments.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 56 57 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 28, 2025.
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Salvia Bioelectronics MySalvia implant

    Salvia raises $60M for neuromodulation migraine system

    BioWorld MedTech
    Salvia Bioelectronics BV raised $60 million in a series B financing round for its minimally invasive implantable neuromodulation device, Mysalvia therapy, which...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe